Psoriasis treatment
Reading File
Finding Sources
Searching PubMed
"psoriasis"[MeSH Terms] AND "therapy"[MeSH Terms]
Searching the Web
psoriasis treatment guidelines 2025 biologics topical systemic
Reading File
Finding Sources
Searching PubMed
"psoriasis" AND "biologic" AND "treatment"
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks and recent evidence. Let me compile a thorough answer.
Psoriasis Treatment
Psoriasis is a chronic, immune-mediated skin disease affecting roughly 2% of the population. Treatment is tailored to disease severity (mild, moderate, severe), body surface area (BSA) involved, location of plaques, and comorbidities. A stepwise approach is standard.
Assessing Severity
| Severity | BSA | PASI | Approach |
|---|---|---|---|
| Mild | <3% | <10 | Topical agents |
| Moderate | 3-10% | 10-20 | Phototherapy + topical |
| Severe | >10% | >20 | Systemic/biologics |
Special circumstances (palmoplantar involvement, nail disease, facial/genital plaques, psoriatic arthritis) may warrant systemic therapy even with limited BSA.
Step 1 - Topical Agents (Mild Disease)
Corticosteroids are the most widely used first-line agents. They reduce inflammation, proliferation, and pruritus. Potency is matched to site: high-potency (e.g., clobetasol, betamethasone) for thick plaques on trunk/extremities; low-potency (hydrocortisone) for face/skin folds. Prolonged use risks skin atrophy, telangiectasias, and adrenal suppression.
Vitamin D analogues (calcipotriene 0.005%, calcitriol) inhibit keratinocyte proliferation and have anti-inflammatory effects. Often combined with corticosteroids (e.g., betamethasone/calcipotriene combination) for additive effect.
Topical retinoids (tazarotene 0.05-0.1%) normalize keratinocyte differentiation. Can be irritating; often used with a corticosteroid.
Newer topical agents:
- Tapinarof cream - aryl hydrocarbon receptor agonist; FDA-approved, reduces epidermal inflammation
- Roflumilast cream - phosphodiesterase-4 (PDE-4) inhibitor; FDA-approved topical, particularly useful for skin folds/genital area
Other topicals: Anthralin (dithranol) - short-contact therapy; stains clothing. Coal tar - keratolytic and anti-inflammatory; useful for scalp disease. Salicylic acid - keratolytic, helps remove scale to improve penetration of other agents.
- Goldman-Cecil Medicine, p. 4279 | Andrews' Diseases of the Skin, p. 238
Step 2 - Phototherapy (Mild-Moderate)
Narrowband UVB (NB-UVB) is the preferred phototherapy modality, given 3x/week. It induces T-cell apoptosis in plaques and is safer than PUVA (no psoralen, no UVA-related carcinogenicity). Suitable for widespread disease, including in pregnancy.
PUVA (Psoralen + UVA): Highly effective but risk of phototoxicity, premature skin aging, and squamous cell carcinoma limits long-term use. Reserved for NB-UVB failures.
Excimer laser (308 nm XeCl): A localized NB-UVB therapy for resistant, localized plaques (scalp, intertriginous areas). Clears plaques approximately twice as fast as conventional UVB with lower cumulative doses - useful for "problem areas."
- Dermatology 2-Volume Set 5e, p. 2863
Step 3 - Conventional Systemic Therapy (Moderate-Severe)
Methotrexate (MTX)
The traditional benchmark systemic agent. A folic acid antagonist that inhibits dihydrofolate reductase and suppresses rapidly dividing cells (keratinocytes, activated T cells).
- Indications: Erythrodermic psoriasis, pustular psoriasis (von Zumbusch), psoriatic arthritis, widespread BSA involvement, severe palmoplantar disease
- Dosing: 15-30 mg/week (oral divided doses 12 h apart, single weekly oral dose, or weekly SC injection). Absorption is unpredictable above 25 mg/week - SC preferred
- Monitoring: Baseline LFTs, renal function, CBC, hepatitis B/C serology, HIV, TB test; monthly LFTs/CBC during induction
- Folic acid 1-4 mg/day co-prescribed to reduce GI side effects
- Key risks: Hepatotoxicity, myelosuppression, pneumonitis, teratogenicity (absolutely contraindicated in pregnancy)
Cyclosporine
- Mechanism: Calcineurin inhibitor; downmodulates proinflammatory epidermal cytokines (IL-2, T-cell activation)
- Dosing: 2-5 mg/kg/day; produces rapid clearance but lesions recur rapidly on stopping
- Duration: Up to 6 months recommended; longer courses increase renal risk
- Monitoring: Blood pressure, serum creatinine (reduce dose if creatinine rises by >1/3 baseline)
- Use: Useful for rapid induction or bridging; not a maintenance drug
Acitretin (Oral Retinoid)
-
Mechanism: Normalizes keratinocyte differentiation and proliferation
-
Dosing: 25-50 mg/day
-
Best for: Pustular psoriasis, erythrodermic psoriasis; also Re-PUVA combination
-
Risks: Teratogenic (must avoid pregnancy for 3 years after stopping); hyperlipidemia, hepatotoxicity, mucocutaneous side effects
-
Combined with: Phototherapy (Re-PUVA/Re-UVB), topical corticosteroids, vitamin D analogues
-
Andrews' Diseases of the Skin, p. 238 | Goldman-Cecil Medicine, p. 4279
Step 4 - Newer Oral Small Molecules
Apremilast (PDE-4 inhibitor)
- 30 mg twice daily; oral
- Modest but meaningful efficacy; no immunosuppression screening required
- Well-tolerated; GI side effects (nausea, diarrhea) common at initiation
- Safe without lab monitoring requirements of older systemics
- Also approved for psoriatic arthritis
Deucravacitinib (TYK-2 inhibitor)
- 6 mg/day; oral, once daily
- Selective tyrosine kinase-2 (TYK-2) inhibitor (spares JAK1/2/3, thus a better safety profile than tofacitinib)
- FDA-approved for moderate-to-severe plaque psoriasis
- More effective than apremilast in head-to-head trials
Step 5 - Biologics (Moderate-Severe; First-line in Many Guidelines)
Biologics are more effective than all oral treatments and are first-line in moderate-to-severe disease in current guidelines. Newer IL-17 and IL-23 inhibitors outperform older agents (ustekinumab, etanercept, adalimumab).
Pre-biologic screening required: TB (Quantiferon/TST), HIV, hepatitis B/C. Do NOT start if active infection is present without treatment.
TNF-alpha Inhibitors
| Drug | Dose |
|---|---|
| Etanercept | 50 mg/week SC |
| Adalimumab | 40 mg every 2 weeks SC |
| Certolizumab pegol | 400 mg every 2 weeks SC |
| Infliximab | 5-10 mg/kg every 8 weeks IV |
TNF inhibitors are also effective for psoriatic arthritis. Infliximab produces fastest onset. Note: paradoxical psoriasis can occur with anti-TNF use.
IL-12/23 Inhibitor
- Ustekinumab - 45 mg (< 100 kg) or 90 mg (> 100 kg) SC at weeks 0, 4, then every 12 weeks
IL-17 Inhibitors (Among Most Effective)
- Secukinumab - 300 mg weekly x5 (loading), then every 4 weeks SC
- Ixekizumab - 160 mg at week 0, then 80 mg every 2 weeks to week 12, then every 4 weeks SC
- Brodalumab - 210 mg at weeks 0, 1, 2 then every 2 weeks SC (IL-17 receptor antibody; carries suicide risk warning)
- Bimekizumab - 320 mg every 4 weeks SC; dual IL-17A/F inhibitor; very high PASI 90/100 rates
IL-23 Inhibitors (Longest Dosing Intervals; Highly Effective)
- Guselkumab - 100 mg at weeks 0, 4, then every 8 weeks SC
- Risankizumab - 150 mg at weeks 0, 4, then every 12 weeks SC
- Tildrakizumab - 100 mg at weeks 0, 4, then every 12 weeks SC
IL-23 inhibitors (targeting p19 subunit) represent a major advance - excellent long-term safety profile, convenient dosing, and sustained PASI 90/100 responses.
For Generalized Pustular Psoriasis
-
Spesolimab (sepolizumab-sbzo) - IL-36 receptor inhibitor; 900 mg IV for acute flares; may repeat at 1 week
-
Goldman-Cecil Medicine, pp. 4278-4279 | Andrews' Diseases of the Skin, pp. 234-238
Special Situations
| Situation | Preferred Approach |
|---|---|
| Scalp psoriasis | Medicated shampoos (coal tar, salicylic acid, ketoconazole), high-potency topical steroids, calcipotriene, excimer laser |
| Nail psoriasis | Topical retinoids, intralesional triamcinolone, systemic agents (methotrexate, biologics) |
| Palmoplantar psoriasis | Potent topical steroids under occlusion, acitretin, PUVA, biologic if severe |
| Psoriatic arthritis | MTX, TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors |
| Erythrodermic psoriasis | Cyclosporine (fastest response), biologics; avoid abrupt steroid withdrawal |
| Pregnancy | NB-UVB preferred; low-potency topicals; MTX/acitretin/biologics generally avoided |
| HIV+ patient | Topical agents/phototherapy first; biologics used with caution, prefer IL-17/IL-23 over TNF inhibitors |
Combination Therapy
Combining modalities can improve efficacy and reduce individual drug toxicities:
- MTX + topical agents (reduces MTX dose)
- MTX + infliximab (reduces immunogenicity of infliximab)
- Acitretin + PUVA ("Re-PUVA") or NB-UVB
- Topical corticosteroid + vitamin D analogue (e.g., Taclonex)
Recent Evidence (2024-2025)
- A 2025 Cochrane network meta-analysis (PMID: 40767824) confirms biologics - particularly IL-17 and IL-23 inhibitors - are the most effective systemic treatments for chronic plaque psoriasis
- A 2024 JAMA Dermatology meta-analysis on biologic response predictors (PMID: 38888917) identified clinical characteristics associated with treatment response
- When biologics fail, a 2025 systematic review (PMID: 40545752) supports switching to a different biologic class rather than within-class switching for better outcomes
- The EuroGuiDerm 2025 update provides updated decision grids for conventional vs. biologic treatment based on comorbidities (psoriatic arthritis, IBD, cardiovascular disease, pregnancy)
Key Monitoring Summary
| Agent | Key Monitoring |
|---|---|
| Methotrexate | CBC, LFTs, creatinine (monthly initially) |
| Cyclosporine | BP, creatinine, electrolytes |
| Acitretin | Lipids, LFTs, pregnancy test |
| Biologics | TB, HIV, Hep B/C pre-treatment |
| Apremilast | Weight (may cause weight loss) |
| Deucravacitinib | Minimal lab monitoring |
This is a shared conversation. Sign in to Orris to start your own chat.